Dreaming about weight loss is easy but to make it realize is difficult. Being overweight or obese is a big curse as carrying those extra pounds makes your health vulnerable and fragile. Shedding those extra pounds by means of diet pills such as Acomplia diet pills help in reducing the weight in a healthy manner. The pill works as appetite suppressants for providing easy and effortless weight loss

Acomplia is also known as rimonabant, which is an anti-obesity drug. Acomplia (rimonabant) is the first in a new class of therapeutic agents which is called Cannabinoid-1 Receptor Blockers (CB1). The drug is used in the treatment of obesity and related conditions.

Acomplia Diet pill works by blocking endogenous cannabinoid binding to CBI receptors in the brain. Activation of these receptors increases appetite. Acomplia diet pills are very effective pills for weight loss which are the only endocannabiboid receptor antagonist in clinical development. Acomplia offers a unique therapeutic approach to appetite control and weight reduction.

• Acomplia is used complementary to diet and exercise to treat obese or overweight patients who suffer from Type 2 diabetes and abnormal levels of fat in the blood.
• Sanofi argues that Acomplia can also prevent the risk of cardiovascular disease.
• Patients with large waist circumference (102 cm in men and 88 cm in women) will mostly benefit from taking the drug.

Some potential anti-obesity drugs have proved effective in the first six months of treatment only to become ineffective as the patient develops resistance to treatment. Data from RIO trials show that Acomplia is effective for maintaining weight loss for a period of at least two years. Patients taking Acomplia lost inches around their waistline which is significant as expanding waistlines are associated with increased risk of heart disease and diabetes. The average waist reduction was 3 inches for patients taking 20mg and 1.3 inches for those on a lower dose. The drug also has the potential as a treatment for smoking cessation because the endocannabiboid system is also involved in the body's response to tobacco dependence. After the first year of treatment 39% of patients taking a high dose lost 10% of their weight.

• In clinical studies, Acomplia has been shown to improve a wide array of Cardio metabolic risk factors as well as promoting sustained weight loss4, 5.
• Approximately half of the observed improvement in HDL-cholesterol, triglycerides and HbA1C (an indicator of blood sugar control) in patients who received .
• Acomplia 20mg was beyond that expected from weight loss alone6.